AG
APLS

Artal Group’s Apellis Pharmaceuticals APLS Stock Holding History

Artal Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,467,080
Closed -$56.3M – 7
2024
Q2 		$56.3M Buy
1,467,080
+151,798
+12% +$6.87M 1.43% 7
2024
Q1 		$77.3M Sell
1,315,282
-106,064
-7% -$6.76M 1.97% 7
2023
Q4 		$85.1M Sell
1,421,346
-243,226
-15% -$12.3M 2.83% 5
2023
Q3 		$63.3M Buy
1,664,572
+614,505
+59% +$27M 2.71% 7
2023
Q2 		$95.7M Sell
1,050,067
-166,245
-14% -$14.3M 2.96% 4
2023
Q1 		$80.2M Buy
1,216,312
+316,312
+35% +$18.3M 4.77% 3
2022
Q4 		$46.5M Sell
900,000
-100,000
-10% -$5.3M 2.6% 11
2022
Q3 		$68.3M Buy
+1,000,000
New +$59.2M 2.91% 5
2022
Q2 		– Sell
-200,000
Closed -$10.2M – 136
2022
Q1 		$10.2M Buy
+200,000
New +$8.83M 0.43% 46
2019
Q2 		– Sell
-300,000
Closed -$5.85M – 105
2019
Q1 		$5.85M Buy
+300,000
New +$4.72M 0.24% 70

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Artal Group's APLS Position: Q3 2024 in Review

Artal Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 1,467,080 shares — an estimated $56.3M sold.

Artal Group first reported a position in APLS in Q1 2019 and held it in 10 quarters. The position peaked at $95.7M in Q2 2023. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Artal Group reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,467,080 Apellis Pharmaceuticals shares in Q3 2024, an estimated $56.3M.
  • Artal Group first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Artal Group's Apellis Pharmaceuticals position peaked at $95.7M in Q2 2023.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.